Apellis Investigates Needle Safety Concerns in Eye Disease Drug
TL;DR
Apellis Pharmaceuticals has identified internal structural variations in the needle used to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients. However, the company has not definitively linked the needle to the cases. Despite one additional case of the severe side effect, the overall frequency remains rare, leading to a 30% rise in Apellis shares as investors believe the safety crisis is abating.
Topics:businesshealth#apellis-pharmaceuticals#eye-disease-drug#health#retinal-occlusive-vasculitis#severe-side-effects#syfovre
- Apellis safety probe of eye disease drug identifies injection needle as possible cause of severe side effect STAT
- Apellis rises 33% on eye drug Syfovre safety update Seeking Alpha
- Apellis (NASDAQ:APLS) Soars After Giving Safety Update on Drug - TipRanks.com TipRanks
- Apellis flags needle problems in hunt for Syfovre side effect source FiercePharma
- Sticking With Apellis: Navigating Syfovre's Safety Measures In A Volatile Market Seeking Alpha
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on STAT